Filing Details
Cogent Biosciences, Inc. (NASDAQ:COGT) filed a Form 8-K with the Securities and Exchange Commission on August 10, 2026, disclosing a material event.
8k filedNASDAQ:COGT
Cogent Biosciences, Inc. (COGT) Reports Material Event to SEC
Cogent Biosciences, Inc. (NASDAQ:COGT) filed a Form 8-K with the Securities and Exchange Commission on August 10, 2026, disclosing a material event.
At publication ·
What changed
Cogent Biosciences, Inc. (NASDAQ:COGT) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Cogent Biosciences, Inc. filed a Form 8-K with the SEC on August 10, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this article.
- The company's stock was trading at $41.53 with a market capitalization of $5.7 billion at the time of the filing.
- 8-K filings report material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
Cogent Biosciences, Inc.'s stock currently trades at $41.53 with a market capitalization of $5.7B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Cogent Biosciences, Inc.'s stock.
All SEC filings for Cogent Biosciences, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View COGT Stock Page
Frequently Asked Questions
Where can I read COGT's SEC filings?
Browse all filings on our COGT SEC filings page.
What types of SEC filings does Cogent Biosciences, Inc. file?
Public companies like Cogent Biosciences, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.